Antidote Treatment Nerve Agent Auto-Injector (ATNAA)

expired opportunity(Expired)
From: Federal Government(Federal)
SPE2DP-23-R-0002

Basic Details

started - 12 Apr, 2024 (16 days ago)

Start Date

12 Apr, 2024 (16 days ago)
due - 05 Apr, 2024 (23 days ago)

Due Date

05 Apr, 2024 (23 days ago)
Pre-Bid Notification

Type

Pre-Bid Notification
SPE2DP-23-R-0002

Identifier

SPE2DP-23-R-0002
DEPT OF DEFENSE

Customer / Agency

DEPT OF DEFENSE (709029)DEFENSE LOGISTICS AGENCY (334240)TROOP SUPPORT MEDICAL (2670)DLA TROOP SUPPORT (32548)

Attachments (1)

unlockUnlock the best of InstantMarkets.

Please Sign In to see more out of InstantMarkets such as history, intelligent business alerts and many more.

Don't have an account yet? Create a free account now.

Solicitation: SPE2DP-23-R-0002Item: ANTIDOTE TREATMENT, NERVE AGENT, Automatic, Dual-Chamber, Pralidoxime Chloride Injection, 300 mg per mL, 2 mL, and Atropine Injection, 2.99 mg per mL, 0.7 mLNSN: 6505-01-362-7427Description: The Defense Logistics Agency Troop Support has a requirement for the supply of Antidote Treatment Nerve Agent Auto-Injector (ATNAA). ATNAA shall be made in accordance with MPID Number 6 dated May 2, 2019.The Solicitation will be issued under authority 10 U.S.C. 2304(c)(1).The Government does not intend to use Part 12 for this acquisition – per FAR 10.002(d)(2).The proposed contract will be a firm-fixed price, indefinite delivery, indefinite quantity type contract. The contract will consist of a base year and four (4) one-year options. The quantities for the base year and each option year are a minimum of 225,000 each and a maximum of 1,000,000 each.Inspection/Acceptance at DestinationFOB DestinationDelivery Destination: Susquehanna, PAProduction Lead Time is 164
days after issuance date of the delivery order (DD1155).All responsible sources may submit a proposal and shall be considered by the Agency.The successful contractor shall have FDA approval to sell ATNAA before award decision.****************************************************************************IMPORTANT NOTICESAvailability of solicitations, FAR 5.102(d) applies, as our office no longer issues solicitations or amendments in paper form. Offeror should register to receive notification of this solicitation or solicitation amendments. The solicitation will be posted on the DLA Internet Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil/. Detailed system requirements and instructions for registration can be found on the DLA DIBBS Home Page accessed on https://www.dibbs.bsm.dla.mil/. Once the solicitation is posted, it will be available for viewing on DIBBS. From the DIBBS homepage, select "Solicitations" from the top bar to search for the solicitation. DIBBS Help can be accessed from the DIBBS homepage. Interested parties are further advised to set up automated notifications of solicitation changes through this website. Solicitation SPE2DP-23-R-0002 is expected to be issued on or around May 2024. ******************************************************************************

MEDICAL SUPPLY CHAIN PHARM FSA 700 ROBBINS AVENUE  PHILADELPHIA , PA 19111  USALocation

Place Of Performance : N/A

Country : United StatesState : PennsylvaniaCity : Philadelphia

Office Address : MEDICAL SUPPLY CHAIN PHARM FSA 700 ROBBINS AVENUE PHILADELPHIA , PA 19111 USA

Country : United StatesState : PennsylvaniaCity : Philadelphia

You may also like

ANTIDOTE TREATMENT

Due: 29 Apr, 2024 (Tomorrow)Agency: Department of Defense

Classification

naicsCode 325414Biological Product (except Diagnostic) Manufacturing
pscCode 6505Drugs and Biologicals